|Product Name||Human Urokinase/uPA ELISA Kit|
|Customs Name||Human Urokinase/uPA ELISA Kit|
|Assay Type||Sandwich ELISA|
|Suitable Sample Type||serum, plasma, cell culture supernates|
|Format||96-well strip plate|
|Storage||4℃ (unopened) standard stored at -20℃, others stored at 4℃ (opened)|
|Sample Volume||50 μl|
|Standard Curve Range||31.25 - 2000 pg/ml|
|Spike Recovery Range||78 % - 118 %|
|Mean Spike Recovery||0.83|
|CV of Intra plate||4.6 % - 5.9 %|
|CV of Inter plate||1.5 % - 5.2 %|
|Components||96-well polystyrene microplate coated with a monoclonal antibody against uPA
Human uPA Standard, lyophilized
uPA Detect Antibody
Assay Buffer (10×)
Washing Buffer (20×)
|Describtion||This assay employs the quantitative sandwich enzyme immunoassay technique for the quantitative detection of human uPA. The Human Urokinase/uPA ELISA is for research use only. Not for diagnostic or therapeutic procedures.
Urokinase, also called urokinase-type plasminogen activator (uPA), is a serine protease involved in degradation of the extracellular matrix and possibly tumor cell migration and proliferation. uPA was originally isolated from human urine, but is present in several physiological locations, such as blood stream and the extracellular matrix. The most important inhibitors of uPA are PAI-1 and PAI-2, which inhibit the protease activity irreversibly. In the extracellular matrix, uPA is tethered to the cell membrane by its interaction to the urokinase receptor.
Elevated expression levels of uPA and several other components of the plasminogen activation system are found to be correlated with tumor malignancy. uPA is a potent marker of invasion and metastasis in a variety of human cancers associated with breast, stomach, colon, bladder, ovary, brain and endometrium. A specific polymorphism in uPA gene is implicated in late-onset Alzheimer disease and also with decreased affinity for fibrin-binding. uPA is used clinically as a thrombolytic agent in the treatment of severe or massive deep venous thrombosis, pulmonary embolism, myocardial infarction, and occluded intravenous or dialysis cannulas. It is also administered intrapleurally to improve the drainage of complicated pleural effusions and empyemas.